Dr. Graff on the Use of Sacituzumab Govitecan in Breast Cancer

Stephanie L. Graff, MD
Published: Monday, Jul 23, 2018



Stephanie L. Graff, MD, director, Breast Program, Sarah Cannon Cancer Institute, associate director, Breast Cancer Research Program, Sarah Cannon Research Institute, discusses the use of sacituzumab govitecan (IMMU-132) in breast cancer.

At the 2018 ASCO Annual Meeting, Aditya Bardia, MD, MPH, of Massachusetts General Hospital, presented updated results on the use of sacituzumab govitecan in the metastatic hormone-receptor (HR)-positive setting. Bardia also presented updated results in the triple-negative space at the 2017 San Antonio Breast Cancer Symposium.

Sacituzumab govitecan has shown tremendous response rates in both groups, says Graff. Graff notes that the data presented by Bardia at the 2018 ASCO Annual Meeting in HR-positive patients are equally as compelling as the data seen in triple-negative breast cancer (TNBC). The maker of the antibody-drug conjugate is seeking an accelerated approval by the FDA. The phase III trial in metastatic TNBC is currently accruing.

The compound is likely to become a breakthrough drug, says Graff, and may be tool for physicians to use across multiple breast cancer subtypes in the clinic very soon.


Stephanie L. Graff, MD, director, Breast Program, Sarah Cannon Cancer Institute, associate director, Breast Cancer Research Program, Sarah Cannon Research Institute, discusses the use of sacituzumab govitecan (IMMU-132) in breast cancer.

At the 2018 ASCO Annual Meeting, Aditya Bardia, MD, MPH, of Massachusetts General Hospital, presented updated results on the use of sacituzumab govitecan in the metastatic hormone-receptor (HR)-positive setting. Bardia also presented updated results in the triple-negative space at the 2017 San Antonio Breast Cancer Symposium.

Sacituzumab govitecan has shown tremendous response rates in both groups, says Graff. Graff notes that the data presented by Bardia at the 2018 ASCO Annual Meeting in HR-positive patients are equally as compelling as the data seen in triple-negative breast cancer (TNBC). The maker of the antibody-drug conjugate is seeking an accelerated approval by the FDA. The phase III trial in metastatic TNBC is currently accruing.

The compound is likely to become a breakthrough drug, says Graff, and may be tool for physicians to use across multiple breast cancer subtypes in the clinic very soon.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x